CPEX Pharmaceuticals Initiates Phase II Clinical Trial of Nasulin(R)

February 24, 2009 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

EXETER, N.H.--(BUSINESS WIRE)--CPEX Pharmaceuticals, Inc. (NASDAQ: CPEX) today announced the initiation of a Phase II clinical trial of Nasulin®, the Company’s intranasal insulin candidate, in subjects with type 2 diabetes.

Twitter
LinkedIn
Facebook
Email
Print

Clinical research Phase II